When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Shares of Myovant Sciences(NYSE: MYOV) are rising today, up by 12% as of 3:03 p.m. EST, after receiving some favorable coverage from the analyst community. The clinical-stage biotechskyrocketed earlier in the week in the wake of strong results in a phase 3 drug trial.
First, Goldman Sachs Group reiterated its buy rating on Myovant and boosted its price target from $18 to $20. Not to be outdone, JMP Securities also reaffirmed its buy rating and has an even more bullish price target of $34. Both of these targets are significantly higher than Thursday's closing price of $12.43.